Page last updated: 2024-08-21

pyrazines and acp-196

pyrazines has been researched along with acp-196 in 160 studies

Research

Studies (160)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	48 (30.00)	24.3611
2020's	112 (70.00)	2.80

Authors

Authors	Studies
Awan, FT; Barrientos, JC; Brown, JR; Byrd, JC; Chaves, J; Covey, T; Devereux, S; Diacovo, TG; Fardis, M; Furman, RR; Ghia, P; Hamdy, A; Harrington, B; Hillmen, P; Huang, J; Izumi, R; Johnson, AJ; Johnson, D; Jones, JA; Kaptein, A; Lannutti, BJ; McGreivy, J; O'Brien, S; Pagel, JM; Rothbaum, W; Schuh, A; Stephens, DM; Wang, X; Wierda, WG; Woyach, J	1
Burki, TK	1
Liu, D; Wu, J; Zhang, M	1
Byrd, JC; Coombes, KR; Coss, CC; Covey, T; Gardner, HL; Gulrajani, M; Hamdy, A; Harrington, BK; Izumi, R; Johnson, AJ; Kaptein, A; Kisseberth, WC; Krejsa, C; London, CA; Rothbaum, W; Russell, DS; Urie, BK; Van Lith, B; Zhang, X	1
Liu, C; Liu, D; Tsui, ST; Wu, J	1
Brown, JR; Davids, MS; Deng, J; Fernandes, SM; Isik, E; Letai, A	1
Kaur, V; Swami, A	1
Golay, J; Introna, M; Ubiali, G	1
Chen, SS; Chiorazzi, N; Covey, T; Dadashian, EL; Herman, SEM; Izumi, R; Krantz, F; Lannutti, BJ; Mora-Jensen, HI; Niemann, CU; Ulrich, R; Wiestner, A	1
Andritsos, LA; Awan, F; Beckwith, K; Byrd, JC; Caligiuri, MA; Cheney, C; Do, P; Flynn, JM; Fraietta, JA; Gordon, A; Johnson, AJ; Jones, JA; June, CH; Lehman, AM; Long, M; Maddocks, KJ; Maus, MV; Mundy, BL; Muthusamy, N; Woyach, JA	1
Fayad, L; Fowler, N; Jain, P; Kanagal-Shamanna, R; Medeiros, LJ; Nastoupil, L; Oki, Y; Romaguera, J; San Lucas, FA; Wang, M; Westin, JR	1
Bantscheff, M; Dittus, L; Muelbaier, M; Werner, T	1
Barf, T; Covey, T; de Zwart, E; Demont, D; Gulrajani, M; Izumi, R; Kaptein, A; Krantz, F; Mittag, D; Pearson, PG; Ulrich, R; van de Kar, B; van Hoek, M; van Lith, B; Verkaik, S	1
Ayres, ML; Balakrishnan, K; Cheung, JP; Gandhi, V; Gay, J; Ivan, C; Keating, MJ; Lamothe, B; Marszalek, JR; Morse, J; Nelson, M; Patel, VK; Wierda, WG	1
Dhillon, S; Markham, A	1
Ansell, SM; Kapoor, P	1
Casasnovas, O; Covey, T; Damaj, G; Davies, A; Doorduijn, J; Dua, R; Dupuis, J; Eek, R; Goy, A; Hamdy, A; Huang, X; Izumi, R; Jacobsen, E; Jurczak, W; Kater, AP; Lamy, T; Le Gouill, S; Morschhauser, F; Oberic, L; Panizo, C; Patel, P; Robak, T; Rothbaum, W; Rule, S; Shah, B; Slatter, JG; Smith, SD; Wang, M; Zinzani, PL	1
Coulter, EM; Cuthill, K; Devereux, S; Folarin, N; Mele, S; Patten, PEM; Pepper, A; Phillips, EH; Townsend, W	1
Brandl, R; Busygina, K; Deckmyn, H; Jamasbi, J; Lorenz, R; Seiler, T; Siess, W; Weber, C	1
Awan, FT; Jurczak, W	1
Liu, Y; Ran, F; Wang, ML; Yang, D; Zhang, D; Zhang, Z; Zhao, G	1
Göckeritz, E; Hallek, M; Hassenrück, F; Herter, S; Klein, C; Knödgen, E; Krause, G; Midda, SH; Neumann, L; Vondey, V	1
Clifford, H; Hardy, AT; Hughes, CE; Huissoon, AP; Malcor, JD; Montague, SJ; Nicolson, PLR; Nock, SH; Pollitt, AY; Pratt, G; Thomas, MR; Tomlinson, MG; Watson, CN; Watson, S; Watson, SP	1
Carrasco, YR; de Bruijn, MJW; Gardeta, SR; Hendriks, RW; Merino-Cortes, SV; Roman-Garcia, S	1
Khan, Y; O'Brien, S	1
Choi, SY; Kim, HJ; Kim, JY; Kim, YG; Kwon, TG; Lee, HJ; Lee, JH; Lee, Y; Pokhrel, NK	1
da Cunha-Bang, C; Niemann, CU	1
Choulwar, S; Deshpande, A; Giri, S; Paul, D; Pokharkar, S; Satheeshkumar, N; Surendran, S	1
Alhalouli, T; Bueso-Ramos, C; Burger, J; Estrov, Z; Ferrajoli, A; Jain, N; Jain, P; Kanagal-Shamanna, R; Kantarjian, HM; Keating, M; Khoury, JD; Luthra, R; Medeiros, LJ; Patel, KP; Routbort, M; Wierda, W	1
Aksenov, S; Al-Huniti, N; Andrew, MA; Edlund, H; Lee, SK; Slatter, JG	1
Długosz-Danecka, M; Jurczak, W; Wang, M	1
Abdelhameed, AS; Alanazi, AM; Almutairi, FM; Bakheit, AH; Hassan, ES; Herqash, RN	1
Garcia, C; Levade, M; Payrastre, B; Series, J; Sié, P; Viaud, J; Ysebaert, L	1
Inwards, D; Witzig, TE	1
Al-Huniti, N; Moorthy, G; Podoll, T; Slatter, JG; Vishwanathan, K; Ware, J; Xu, Y; Zhou, D	1
Bernlochner, I; Busygina, K; Denzinger, V; Lorenz, R; Siess, W; Weber, C	1
Awan, FT; Bibikova, E; Brown, JR; Byrd, JC; Charuworn, P; Frigault, MM; Furman, RR; Hamdy, A; Hillmen, P; Izumi, R; Linghu, B; Pagel, JM; Patel, P; Schuh, A; Stephens, DM; Wang, MH; Woyach, J	1
Appleby, N; Boucher, R; Cabes, M; Eyre, TA; Fox, S; Hillmen, P; Jackson, A; Rawstron, A; Schuh, A; Yates, F	1
Alinari, L; Bond, DA; Maddocks, K	1
Andrew, MA; Bailey, GR; Barker, R; Ingallinera, TG; Krejsa, CM; Mann, JC; Meehan, E; Moir, AJ; Murphy, DS; Pepin, XJH; Plumb, AP; Sanderson, NJ; Slatter, JG	1
Blanazs, A; Grover, S; Ingallinera, TG; Mann, JC; Pepin, XJH; Sanderson, NJ	1
Al, MJ; Geenen, JW; Goettsch, WG; Hövels, AM; Leufkens, HGM; Vreman, RA	1
Bernasconi, E; Bertoni, F; Cascione, L; Dirnhofer, S; Gaudio, E; Gerlach, MM; Mascia, M; Priebe, V; Spriano, F; Stathis, A; Tarantelli, C; Targa, A; Zucca, E	1
Cao, X; Liu, X; Xia, S; Xu, S	1
Al Zoubi, S; Chiazza, F; Coldewey, SM; Collino, M; Collotta, D; Martin, L; O'Riordan, CE; Purvis, GSD; Stiehler, L; Thiemermann, C; Wissuwa, B	1
Casasnovas, O; Damaj, G; Davies, A; Doorduijn, JK; Dupuis, J; Długosz-Danecka, M; Eek, R; Frigault, MM; Goy, A; Izumi, R; Jacobsen, E; Jain, P; Kater, AP; Lamy, T; Le Gouill, S; Morschhauser, F; Nguyen, D; Oberic, L; Panizo, C; Patel, P; Robak, T; Rule, S; Shah, B; Smith, SD; Wang, M; Yin, M; Zinzani, PL	1
Castillo, JJ; Treon, SP	1
Abhyankar, S; Kabadi, SM; Signorovitch, J; Song, J; Telford, C; Yao, Z; Zhao, J	1
Abu-Rayyan, M; Al-Janazreh, H; Atrash, M; Botta, C; Cutrona, G; Galimberti, S; Gentile, M; Martino, M; Morabito, F; Morabito, L; Recchia, AG; Skafi, M; Vigna, E	1
Aguilar-Company, J; Los-Arcos, I; Ruiz-Camps, I	1
Yaqub, F	1
Aurran-Schleinitz, T; Chen, DY; Cheson, BD; D'Sa, S; Forconi, F; Frigault, MM; Furman, RR; Greenwald, D; Hamdy, A; Iyengar, S; Izumi, R; Kastritis, E; Kersten, MJ; Kothari, J; Lee, SK; McCarthy, H; Minnema, MC; Mittag, D; Owen, RG; Patel, P; Rule, S; Thomas, SK; Tournilhac, O; Walter, H; Wei, H; Zinzani, PL	1
Dean, JP; Gururaja, T; Hill, RJ; Hopper, M; Kinoshita, T; Mongan, A	1
Awan, FT; Barrientos, J; Brown, JR; Burke, K; Byrd, JC; Chaves, JM; Covey, T; Devereux, S; Frigault, MM; Furman, RR; Ghia, P; Gulrajani, M; Hamdy, A; Hillmen, P; Izumi, R; Martin, P; O'Brien, S; Pagel, JM; Patel, P; Rothbaum, W; Schuh, A; Stephens, DM; Wang, MH; Wierda, WG; Woyach, JA	1
Baturevych, A; Clouser, CR; Hause, RJ; Johnstone, TG; Jones, JC; Krejsa, CM; Ponce, R; Ports, MO; Qin, JS; Ragan, SP; Salmon, RA	1
Andersen, BL; Bhat, SA; Blachly, JS; Byrd, JC; Frigault, MM; Gulrajani, M; Hamdy, A; Izumi, R; Jianfar, M; Lozanski, G; Munugalavadla, V; Quah, C; Rogers, KA; Wang, MH; Weiss, DM; Woyach, JA	1
Alsadhan, A; Bibikova, E; Cheung, J; Covey, T; Gaglione, EM; Gulrajani, M; Hamdy, A; Herman, SEM; Izumi, R; Nierman, P; Patel, P; Sun, C; Wiestner, A	1
Benson, AB; Davis, RE; Javle, M; Kumar-Sinha, C; Lopez, CD; Maitra, A; Mettu, NB; Munugalavadla, V; Neelapu, S; Overman, M; Parra, ER; Patel, P; Tao, L; Vats, P; Xiao, L	1
Bossory Goike, L; Dean, S	1
Ahn, IE; Cheung, J; Covey, T; Farooqui, MZH; Gaglione, EM; Gulrajani, M; Hamdy, A; Harris, HM; Herman, SEM; Izumi, R; Kendall, EK; Maric, I; Nierman, P; Patel, P; Pittaluga, S; Pleyer, C; Stetler-Stevenson, M; Sun, C; Wang, MH; Wiestner, A; Yuan, CM	1
Campbell, M; Hanna, KS; Husak, A; Sturm, S	1
Davids, MS	1
Banerji, V; Byrd, JC; Corbett, G; Coutre, S; Cymbalista, F; Egyed, M; Flinn, IW; Fogliatto, LM; Follows, G; Ghia, P; Herishanu, Y; Izumi, R; Janssens, A; Jurczak, W; Kamdar, M; Karlsson, K; Munir, T; Munugalavadla, V; Pagel, JM; Patel, P; Salles, G; Sharman, JP; Skarbnik, A; Walewska, R; Walker, P; Wang, MH; Wierda, WG; Wong, S; Woyach, JA	1
Chong, EA; Davids, MS; Mato, AR; Roeker, LE; Schuster, SJ; Shadman, M	1
Romero, D	1
Bhalla, S; Gabrilove, J; Sigel, K; Thibaud, S; Tremblay, D; Zimmerman, B	1
Avery, E; Campbell, P; de la Serna, J; Dolan, S; Ghia, P; Illes, A; Jacob, A; Jurczak, W; Kaplan, P; Kozak, T; Kraychok, I; Lee, JH; Liang, W; Lysak, D; Musuraca, G; Patel, P; Pluta, A; Quah, C; Simkovic, M; Wach, M	1
Bochner, BS; Chhiba, KD; Dispenza, MC; Krier-Burris, RA; Robida, PA; Undem, BJ	1
Baselga, J; Chung, KK; Collen, J; Desai, JV; Goy, A; Hamdy, A; Izumi, R; Lionakis, MS; Monticelli, MA; Roschewski, M; Rose, K; Roshon, M; Roswarski, J; Sharman, JP; Staudt, LM; Wilson, WH; Wright, GW; Wrzesinski, SH; Zarakas, MA	1
Beylot-Barry, M; Protin, C; Recher, C; Sibaud, V; Vigarios, E; Ysebaert, L	1
Thompson, PA	1
Badillo, M; Chen, W; Guerrero, M; Nava, D; Rosa, M; Wang, M	1
Bertino, EM; Bhat, SA; Bond, DA; Byrd, JC; Fisher, JL; Grever, MR; Huang, Y; Jaglowski, SM; Maddocks, KJ; Owen, DH; Rogers, KA; Ruppert, AS; Woyach, JA	1
Bamodu, OA; Chao, TY; Haryana, SM; Hsiao, M; Hsu, WM; Liu, YL; Pikatan, NW; Yeh, CT	1
Carroll, M; Chalmers, JD; De Soyza, A; Dixon, R; Doherty, J; Duncan, G; Felton, T; Gordon, A; Griffiths, G; Ho, LP; Lewis, KE; Martinez-Alier, N; McGarvey, L; O'Kelly, M; Page, C; Phekoo, K; Read, RC; Shankar-Hari, M; Singh, D; Summers, C; Sykes, J; Walles, R; Wilkinson, T	1
Alva, AS; Appleman, LJ; Bitman, B; Burke, JM; Cetnar, J; Chan, C; Fleming, MT; George, DJ; Hahn, NM; Harrison, MR; Izumi, R; Milowsky, MI; Mortazavi, A; Munugalavadla, V; O'Donnell, PH; Patel, P; Schmidt, EV; Shore, N; Sonpavde, GP; Staats, J; Weinhold, KJ; Zhang, T	1
Agarwal, N; Grivas, P; Khaki, AR; Pal, SK	1
Bond, DA; Maddocks, KJ	1
Gao, A; Gao, W; Huo, D; Ran, X; Sheng, Z; Song, S; Yu, M; Zhu, H	1
Fancher, KM; Pappacena, JJ	1
Jiang, Z; Lin, G; Shi, L; Wang, Y; Zhang, Y	1
Abhyankar, S; Davids, MS; Le Nouveau, P; Leblond, V; Padhiar, A; Singh, G; Waweru, C	1
Al-Sanea, MM; Alharbi, KS; El-Mesery, ME; Gomaa, HAM; Hazem, SH; Shaker, ME	1
Callender, LA; Coldewey, SM; Collino, M; Collotta, D; Ferreira Alves, G; Greaves, DR; Krieg, N; Mohammad, S; O'Riordan, CE; Purvis, GSD; Sheikh, MH; Thiemermann, C; Wissuwa, B	1
Bartoli, L; Messori, A	1
Han, M; He, J; Li, J; Liu, C; Liu, Q; Yuan, H; Zhou, X	1
Giannarelli, D; Molica, S; Montserrat, E	1
Danilov, AV; Persky, DO	1
Barrientos, JC; Rhodes, JM	1
Lamanna, N; Lipsky, A	1
Lim, KJC; Tam, CS	1
Macip, S; Massip-Salcedo, M; Qusairy, Z; Rada, M	1
Dlugosz-Danecka, M; Ghia, P; Jurczak, W; Scarfò, L	1
Asch, A; Autry, MT; Balakrishna, P; Keruakous, AR; Schmidt, SA	1
Benner, B; Carson, WE	1
Camarero, J; Delgado, J; Enzmann, H; Garcia-Ochoa, B; Gisselbrecht, C; Josephson, F; Lopez-Anglada, L; Papadouli, I; Pignatti, F; Prieto-Fernandez, C; van Hennik, PB	1
Badillo, M; Flowers, C; Jain, P; Kanagal-Shamanna, R; Lee, HJ; Li, S; Nair, R; Nastoupil, L; Navsaria, L; Ok, CY; Patel, KM; Tang, G; Vega, F; Wang, L; Wang, ML; Yin, CC; Zhang, S	1
Berglöf, A; Estupiñán, HY; Mohammad, DK; Schaafsma, GCP; Shi, Y; Smith, CIE; Vihinen, M; Wang, Q; Yu, L; Zain, R; Zhou, L	1
Ando, K; Ennishi, D; Hayashi, N; Ichikawa, S; Iizumi, S; Izutsu, K; Kato, K; Kawasumi, H; Kumagai, K; Murayama, K; Nagai, H; Patel, P; Shibayama, H; Suzumiya, J; Yamamoto, K	1
Allan, JN; Cheson, BD; Coleman, M; Frigault, MM; Izumi, R; Jones, D; Kipps, TJ; Patel, P; Quah, C; Raman, RK; Rogers, KA; Sharman, JP; Thompson, PA; Wang, MH	1
Barrientos, JC; Brown, JR; Byrd, JC; Devereux, S; Furman, RR; Hamdy, A; Hillmen, P; Izumi, R; Jain, N; Martin, P; O'Brien, S; Pagel, JM; Patel, P; Stephens, DM; Wang, MH; Wierda, WG; Woyach, JA	1
Baek, M; Brown, JR; Byrd, JC; Chernyukhin, N; Christian, B; Dyer, MJS; Furman, RR; Ghia, P; Hamdy, AM; Hillmen, P; Izumi, R; Jurczak, W; Lezhava, T; O'Brien, SM; Owen, RG; Pagel, JM; Patel, P; Rule, S; Sharman, JP; Stephens, DM; Streetly, MJ; Sun, C; Wang, M	1
Abhyankar, S; Davids, MS; Ringshausen, I; Telford, C; Waweru, C	1
Cao, J; Fan, X; Jiang, L; Liu, Y; Wang, X; Wang, Z; Xia, Y; Yan, M	1
Ahn, IE; Baptista, MJ; Blackburn, A; Eik, D; Gaglione, EM; Kendall, EK; Keyvanfar, K; Mhibik, M; Qi, J; Rader, C; Sun, C; Wiestner, A	1
Mato, AR; Thompson, MC	1
Calvo, R; De Vos, S; Dyer, MJS; Flowers, CR; Frigault, MM; Maddocks, KJ; Patel, P; Ruan, J; Rule, S; Strati, P; Wei, H; Xu, Y	1
Woyach, JA	1
Ahn, IE; Brown, JR	1
Bellanti, F; Buil-Bruna, N; Edlund, H; Liu, H; Sharma, S; Tomkinson, H; Vishwanathan, K; Ware, J	1
Blackmon, A; O'Brien, S	1
Burke, KA; Carnevalli, LS; Cheung, J; Clevenger, TN; Collins, GP; Cunningham, D; Dougherty, BA; Flinn, I; Fox, CP; Frigault, MM; Goy, A; Gribben, J; Hamdy, A; Harrington, EA; Izumi, R; MacDonald, A; Nowakowski, GS; Nuttall, B; Pease, JE; Raymond, A; Roschewski, M; Schalkwijk, S; Stetson, D; Tao, L; Vallurupalli, A; Vose, JM; Willis, B; Yang, B	1
Li, J; Miao, Y; Xu, W	1
Mulder, TA; Österborg, A; Palma, M	1
Byrd, JC; Chanan-Khan, A; Furman, RR; Garcia-Marco, JA; Ghia, P; Hamdy, A; Higgins, K; Hillmen, P; Illés, A; Izumi, R; Jurczak, W; Kater, AP; Kay, N; Lepretre, S; Mato, A; O'Brien, S; Patel, P; Pinilla-Ibarz, J; Robak, T; Rothbaum, W; Seymour, JF; Sohoni, S; Stilgenbauer, S; Yenerel, MN	1
Corneth, OBJ; de Bruijn, MJW; Hendriks, RW; Neys, SFH; Rip, J; Singh, SP; van Hulst, JAC; Willar, J	1
Castillo, JJ; Sarosiek, S; Treon, SP	1
Armand, P; Arnason, JE; Brown, JR; Crombie, JL; Davids, MS; Fisher, DC; Jacobson, CA; Kim, AI; LaCasce, AS; Lampson, BL; Lowney, JC; Montegaard, J; Ng, SY; Patterson, V; Pazienza, S; Tyekucheva, S; Wang, Z; Weinstock, M	1
Alonso, C; Ángel Hernández-Rivas, J; Bastidas, G; Bastos-Oreiro, M; Bocanegra, A; Carpio, C; Comai, A; Cordoba, R; De Nicolás, R; Del Campo, R; Fernández-Cruz, A; García-Suárez, J; Grande, C; Jiménez-Ubieto, A; López-Guillermo, A; López-Jiménez, J; Luis Plana, J; Marquet, J; Martín, X; Martínez-López, J; Mas-Ochoa, C; Morillo, D; Navarro-Matilla, B; Núñez, L; Prat, M; Romero, S; Ruiz-Camps, I; Seri, C; Serna, Á; Stefania Infante, M; Vásquez, L; Villafuerte, P	1
Brown, JR; Byrd, JC; Ferrajoli, A; Furman, RR; Ghia, P; Hillmen, P; Jurczak, W; Kuptsova-Clarkson, N; Moslehi, J; Pagel, JM; Patel, P; Sharman, JP; Stephens, DM; Sun, C; Tao, L	1
Gaballa, S; Pinilla-Ibarz, J	1
Bohne, LJ; Dorey, TW; Jansen, HJ; Jones, DL; Liu, Y; Rose, RA; Tuomi, JM	1
Brown, JR; Byrd, JC; Cheung, J; Eyre, TA; Furman, RR; Ghia, P; Hamdy, A; Hillmen, P; Izumi, R; Pagel, JM; Patel, P; Schuh, A; Wang, MH; Wierda, WG; Xu, Y	1
Al-Sawaf, O; Fischer, K	1
Trentin, L; Visentin, A	1
Brown, JR	1
Nierman, P	1
Adkins, D; Algazi, A; Betts, CB; Cohen, EEW; Coussens, LM; Goldschmidt, JH; Guarino, MJ; Jimeno, A; Maloney, L; Munugalavadla, V; Nadler, E; Nemunaitis, J; Patel, P; Tao, L; Taylor, MH	1
Shah, HR; Stephens, DM	1
Izumi, R; Kuo, H; Kwan, A; Madere, J; Marbury, T; Nguyen, H; Podoll, T; Preston, RA; Sharma, S; Slatter, JG; Smith, W; Vishwanathan, K; Ware, JA; Xu, Y	1
Allsup, DJ; Arman, M; Booth, Z; Caserta, S; Chacko, AR; Hart, SP; Jarvis, J; Khan, S; Naylor-Adamson, L; Rivero, F	1
Banerji, V; Byrd, JC; Corbett, G; Coutre, S; Cymbalista, F; Egyed, M; Ferrant, E; Flinn, IW; Fogliatto, LM; Follows, G; Ghia, P; Herishanu, Y; Janssens, A; Jurczak, W; Kamdar, M; Karlsson, K; Munir, T; Munugalavadla, V; Pagel, JM; Sharman, JP; Skarbnik, A; Walewska, R; Walker, P; Wang, MH; Wierda, WG; Woyach, JA; Yu, T	1
Ghia, P	1
Bhattacharyya, A; Kim, J; Truong, K; Wells, J	1
Borbely, J; Egyed, M; Illes, A; Lueff, S	1
Chen, B; Cheung, J; Lai, R; Sarvaria, N; Sharma, S; Vishwanathan, K; Ware, J; Wei, H; Yotvat, M; Zhou, D; Zhou, L	1
Baran, AM; Barr, PM; Blick-Nitko, SK; Chu, CC; Elliott, MR; Izumi, R; Munugalavadla, V; Peterson, DR; Pinney, JJ; Van DerMeid, KR; Whitehead, HE; Zent, CS	1
Barr, PM; Calvo, R; Melear, JM; O'Brien, SM; Patel, P; Roschewski, MJ; Sharman, JP; Smith, SD; Spurgeon, SE; Yang, H	1
Robak, T; Wolska-Washer, A	1
Cheung, J; Gupta, A; Han, D; Majewski, M; Mann, J; Munugalavadla, V; Patel, P; Pepin, X; Sharma, S; Sheridan, L; Tomkinson, H; Townsley, D; Ware, JA; Wei, H; Zheng, L	1
Black, GS; Byrd, JC; Huang, X; Marth, GT; Misra, S; Qiao, Y; Rogers, KA; Stephens, DM; Tarapcsak, S; Woyach, JA	1
Abraham, I; Alrawashdh, N; Erstad, B; McBride, A; Persky, DO; Sweasy, J	1
Brüggemann, M; Cramer, P; Eichhorst, B; Fink, AM; Fischer, K; Franzen, F; Fürstenau, M; Giza, A; Hallek, M; Ritgen, M; Robrecht, S; Schilhabel, A; Schneider, C; Stilgenbauer, S; Tausch, E; Weiss, J	1
Liu, H; Liu, Y; Wang, G; Xu, L; Yi, B; Yu, S	1
Borkar, RM; Gunnam, S; P, R; Rayala, VVSPK; Trivedi, KA; Upadhyayula, SM	1
Budde, LE; Calvo, R; Champion, R; Coleman, M; Geethakumari, PR; Higgins, K; Lam, S; Levy, MY; Lossos, IS; Ma, S; Patti, C; Strati, P	1
Dong, F; Hu, Y; Jiang, D; Song, Z; Zhao, R	1
Addison, D; Awan, F; Azali, L; Bhat, SA; Byrd, JC; Chen, ST; Gambril, J; Grever, M; Kalathoor, S; Kittai, A; Palettas, M; Rogers, KA; Rosen, L; Ruz, P; Wiczer, TE; Woyach, J; Zhao, Q	1
Al-Sawaf, O; Böttcher, S; Brüggemann, M; Cramer, P; Dreger, P; Eichhorst, B; Fink, AM; Fischer, K; Fürstenau, M; Giza, A; Hallek, M; Kneba, M; Kreuzer, KA; Langerbeins, P; Ritgen, M; Robrecht, S; Schetelig, J; Schilhabel, A; Schneider, C; Stilgenbauer, S; Tausch, E; Zhang, C	1
Asadi, M; Warshel, A; Xie, WJ	1
Golla, VM; Kanchupalli, VK; Khemchandani, R; Kushwah, BS; Padhy, HP; Samanthula, G; Sonti, R	1
Booth, S; Bye, AP; Cowen, LG; Desborough, MJ; Eyre, TA; Gibbins, JM; Kesavan, M; Kriek, N; Lees, C; Prodger, C; Rawlings, SJ; Sage, T; Shefferd, K	1
DiPippo, AJ; Ferrajoli, A; Lee, J; McGhie, A	1
Azali, L; Bhat, SA; Byrd, JC; Grever, MR; Kittai, AS; Kumar, PS; Palettas, M; Pollauf, AJ; Rogers, KA; Rosen, L; Wiczer, T; Woyach, JA; Zheng, A	1
Bruzzese, A; Filippelli, G; Gentile, M; Iaccino, E; Lucia, E; Martino, EA; Mendicino, F; Morabito, F; Neri, A; Olivito, V; Vigna, E	1
Alsarhani, WK; AlShaker, S; Chan, CC; Lichter, M	1
Bochner, BS; Dispenza, MC; Dunnam, C; MacGlashan, DW; Suresh, RV; Vaidya, D; Wood, RA	1
Ghia, P; Hettle, R; Kittai, AS; Miranda, M; Palazuelos-Munoz, S; Roos, J; Shetty, V; Skarbnik, A; Yong, ASM	1
Lehman, VT; Ranganath, N; Tawfiq, RK	1

Reviews

40 review(s) available for pyrazines and acp-196

Article	Year
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. Journal of hematology & oncology, 2016, Mar-09, Volume: 9 Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Benzamides; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Treatment Outcome; Xenograft Model Antitumor Assays	2016
Second-generation inhibitors of Bruton tyrosine kinase. Journal of hematology & oncology, 2016, 09-02, Volume: 9, Issue:1 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Drug Resistance, Neoplasm; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines	2016
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. Annals of hematology, 2017, Volume: 96, Issue:7 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Diarrhea; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nausea; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Sulfonamides	2017
Acalabrutinib: First Global Approval. Drugs, 2018, Volume: 78, Issue:1 Topics: Adult; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Drug Approval; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Treatment Outcome; United States; United States Food and Drug Administration	2018
Use of acalabrutinib in patients with mantle cell lymphoma. Expert review of hematology, 2018, Volume: 11, Issue:6 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Humans; Infection Control; Infections; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines	2018
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors. Archiv der Pharmazie, 2018, Volume: 351, Issue:7 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Autoimmune Diseases; Benzamides; Drug Design; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines	2018
Acalabrutinib and its use in treatment of chronic lymphocytic leukemia. Future oncology (London, England), 2019, Volume: 15, Issue:6 Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome	2019
Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies. Drugs, 2018, Volume: 78, Issue:16 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Benzamides; Drug Therapy, Combination; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines	2018
Acalabrutinib for adults with mantle cell lymphoma. Expert review of clinical pharmacology, 2019, Volume: 12, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Humans; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Survival Rate	2019
Acalabrutinib for mantle cell lymphoma. Blood, 2019, 06-13, Volume: 133, Issue:24 Topics: Antineoplastic Agents; Benzamides; Humans; Lymphoma, Mantle-Cell; Protein Kinase Inhibitors; Pyrazines	2019
Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs? Thrombosis and haemostasis, 2019, Volume: 119, Issue:8 Topics: Adenine; Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Agammaglobulinemia; Animals; Arteries; B-Lymphocytes; Benzamides; Blood Platelets; Cell Differentiation; Genetic Diseases, X-Linked; Hemorrhage; Humans; Imidazoles; Mice; Piperidines; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Thrombosis	2019
Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions. Clinical advances in hematology & oncology : H&O, 2019, Volume: 17, Issue:4 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cardiovascular Diseases; Clinical Trials as Topic; Forecasting; Gastrointestinal Neoplasms; Hemorrhage; Humans; Immunologic Factors; Lymphocytosis; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Neoplasm Proteins; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Salvage Therapy	2019
What is new in the treatment of Waldenstrom macroglobulinemia? Leukemia, 2019, Volume: 33, Issue:11 Topics: Adenine; Antibodies, Monoclonal; Antigens, CD20; Benzamides; Bone Marrow; Disease-Free Survival; Hematology; Humans; Immunoglobulin M; Mutation; Piperidines; Proteasome Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Waldenstrom Macroglobulinemia	2019
Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma. Clinical therapeutics, 2019, Volume: 41, Issue:11 Topics: Adenine; Antineoplastic Agents; Benzamides; Bortezomib; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrazines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Treatment Outcome	2019
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:1 Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Lymphoma, Mantle-Cell; Protein Kinase Inhibitors; Pyrazines	2020
Risk of infection associated with new therapies for lymphoproliferative syndromes. Medicina clinica, 2020, 02-14, Volume: 154, Issue:3 Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Communicable Disease Control; Humans; Immune Checkpoint Inhibitors; Infections; Lymphoproliferative Disorders; Piperidines; Purines; Pyrazines; Quinazolinones; Risk; Rituximab; Sulfonamides; Syndrome	2020
The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:5 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Benzamides; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines	2020
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors. American journal of clinical dermatology, 2020, Volume: 21, Issue:6 Topics: Adenine; Administration, Cutaneous; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Biopsy; Drug Eruptions; Ecchymosis; Emollients; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Necrosis; Patient Education as Topic; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Severity of Illness Index; Signal Transduction; Skin; Skin Care	2020
Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma. Hematology/oncology clinics of North America, 2020, Volume: 34, Issue:5 Topics: Agammaglobulinaemia Tyrosine Kinase; Benzamides; Humans; Lymphoma, Mantle-Cell; Neoplasm Proteins; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines	2020
Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis. Leukemia & lymphoma, 2020, Volume: 61, Issue:14 Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Network Meta-Analysis; Piperidines; Prospective Studies; Pyrazines; Sulfonamides	2020
Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis. Clinical therapeutics, 2020, Volume: 42, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Network Meta-Analysis; Pyrazines; Randomized Controlled Trials as Topic	2020
Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis. Clinical lymphoma, myeloma & leukemia, 2021, Volume: 21, Issue:4 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Mutation; Network Meta-Analysis; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Sulfonamides; Tumor Suppressor Protein p53	2021
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies. British journal of haematology, 2021, Volume: 193, Issue:1 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Clinical Trials as Topic; Disease Progression; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Middle Aged; Piperidines; Practice Patterns, Physicians'; Pyrazines; Safety; Treatment Outcome; United States; United States Food and Drug Administration	2021
Chemotherapy-free frontline therapy for CLL: is it worth it? Hematology. American Society of Hematology. Education Program, 2020, 12-04, Volume: 2020, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pyrazines; Rituximab; Sulfonamides	2020
Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology. American Society of Hematology. Education Program, 2020, 12-04, Volume: 2020, Issue:1 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Arrhythmias, Cardiac; Arthralgia; Benzamides; Diarrhea; Hemorrhage; Humans; Hypertension; Infection Control; Infections; Male; Piperidines; Protein Kinase Inhibitors; Pyrazines	2020
Zanubrutinib for the treatment of Waldenström Macroglobulinemia. Expert review of hematology, 2020, Volume: 13, Issue:12 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Atrial Fibrillation; Benzamides; Central Nervous System Diseases; Clinical Trials as Topic; Febrile Neutropenia; Gastrointestinal Diseases; Gene Expression Regulation, Neoplastic; Humans; Multicenter Studies as Topic; Myeloid Differentiation Factor 88; Neoplasm Proteins; NF-kappa B; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Receptors, CXCR4; Recurrence; Salvage Therapy; Signal Transduction; Treatment Outcome; Waldenstrom Macroglobulinemia	2020
Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy. Molecular cancer research : MCR, 2021, Volume: 19, Issue:4 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antiviral Agents; Benzamides; COVID-19; COVID-19 Drug Treatment; Humans; Lung; Molecular Targeted Therapy; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrazines; Thrombosis	2021
EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia. The oncologist, 2021, Volume: 26, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Pyrazines; Rituximab	2021
Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors. Hematology/oncology clinics of North America, 2021, Volume: 35, Issue:4 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Sulfonamides	2021
Targeting Bruton's Tyrosine Kinase in CLL. Frontiers in immunology, 2021, Volume: 12 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Treatment Outcome	2021
An update on acalabrutinib to treat chronic lymphocytic leukemia. Drugs of today (Barcelona, Spain : 1998), 2021, Volume: 57, Issue:7 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Pyrazines; Pyrimidines	2021
Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia. Expert opinion on drug metabolism & toxicology, 2021, Volume: 17, Issue:9 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines	2021
BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects. Frontiers in immunology, 2021, Volume: 12 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Humans; Infection Control; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines	2021
How to Sequence Therapies in Waldenström Macroglobulinemia. Current treatment options in oncology, 2021, 08-23, Volume: 22, Issue:10 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Humans; Mutation; Myeloid Differentiation Factor 88; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Waldenstrom Macroglobulinemia	2021
BTK Inhibitors in Chronic Lymphocytic Leukemia. Current hematologic malignancy reports, 2021, Volume: 16, Issue:5 Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Development; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines	2021
Acalabrutinib: Nursing Considerations for Use in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. Clinical journal of oncology nursing, 2021, 12-01, Volume: 25, Issue:6 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines	2021
Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia. Future oncology (London, England), 2022, Volume: 18, Issue:7 Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazines; Pyrazoles; Pyrimidines	2022
Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. Expert review of hematology, 2022, Volume: 15, Issue:3 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Pyrazines	2022
Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2022, Volume: 25, Issue:10 Topics: Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Cost-Benefit Analysis; Financial Stress; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Markov Chains; Pyrazines; Quality-Adjusted Life Years; Sulfonamides	2022
Risk of bleeding associated with BTK inhibitor monotherapy: a systematic review and meta-analysis of randomized controlled trials. Expert review of clinical pharmacology, 2022, Volume: 15, Issue:8 Topics: Benzamides; Hemorrhage; Humans; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic	2022

Trials

35 trial(s) available for pyrazines and acp-196

Article	Year
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. The New England journal of medicine, 2016, Jan-28, Volume: 374, Issue:4 Topics: Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Benzamides; Chromosome Deletion; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Headache; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Recurrence	2016
Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. PloS one, 2016, Volume: 11, Issue:7 Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Anorexia; Antineoplastic Agents; B-Lymphocytes; Benzamides; Cell Line, Tumor; Diarrhea; Disease Models, Animal; Disease-Free Survival; Dogs; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Humans; Lethargy; Lymphoma, Large B-Cell, Diffuse; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Vomiting; Weight Loss	2016
Ibrutinib treatment improves T cell number and function in CLL patients. The Journal of clinical investigation, 2017, Aug-01, Volume: 127, Issue:8 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Antigens, CD; Antineoplastic Agents; Benzamides; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cohort Studies; CTLA-4 Antigen; Female; Humans; Immunosuppressive Agents; Immunotherapy; Interleukin-10; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Lymphocyte Activation; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; Piperidines; Programmed Cell Death 1 Receptor; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Immunologic; T-Lymphocytes	2017
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet (London, England), 2018, 02-17, Volume: 391, Issue:10121 Topics: Aged; Benzamides; Dose-Response Relationship, Drug; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Recurrence; Survival Analysis; Treatment Outcome	2018
Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies. Clinical pharmacokinetics, 2019, Volume: 58, Issue:5 Topics: Adolescent; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Healthy Volunteers; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Models, Biological; Protein Kinase Inhibitors; Pyrazines; Young Adult	2019
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood advances, 2019, 05-14, Volume: 3, Issue:9 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Phosphorylation; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Treatment Outcome	2019
The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in BMC cancer, 2019, May-20, Volume: 19, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Prospective Studies; Pyrazines; Recurrence; Research Design; Rituximab; Treatment Outcome; Vincristine; Young Adult	2019
Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia. Applied health economics and health policy, 2019, Volume: 17, Issue:6 Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Pyrazines; Quality-Adjusted Life Years; State Medicine; Survival Analysis; United Kingdom	2019
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia, 2019, Volume: 33, Issue:11 Topics: Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Pyrazines; Time Factors; Treatment Outcome	2019
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. The Lancet. Haematology, 2020, Volume: 7, Issue:2 Topics: Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Neoplasm Proteins; Neutropenia; Pain; Protein Kinase Inhibitors; Pyrazines; Quality of Life; Recurrence; Respiratory Tract Infections; Salvage Therapy; Treatment Outcome; Waldenstrom Macroglobulinemia	2020
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood, 2020, 04-09, Volume: 135, Issue:15 Topics: Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome	2020
Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia. Cancer discovery, 2020, Volume: 10, Issue:3 Topics: Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Proliferation; Drug Administration Schedule; Female; Humans; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pyrazines; Rituximab; Treatment Outcome	2020
Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 06-15, Volume: 26, Issue:12 Topics: Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Pyrazines	2020
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. Journal for immunotherapy of cancer, 2020, Volume: 8, Issue:1 Topics: Administration, Intravenous; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Pancreatic Ductal; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myeloid-Derived Suppressor Cells; Pancreatic Neoplasms; Programmed Cell Death 1 Receptor; Progression-Free Survival; Proof of Concept Study; Pyrazines; Tumor Microenvironment	2020
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib. Blood, 2020, 07-02, Volume: 136, Issue:1 Topics: Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Enzyme Induction; Female; Headache; Hematologic Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Proteins; Pain; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; RNA-Seq; RNA, Messenger; RNA, Neoplasm; Transcriptome; Treatment Outcome	2020
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet (London, England), 2020, 04-18, Volume: 395, Issue:10232 Topics: Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chlorambucil; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Progression-Free Survival; Pyrazines	2020
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 09-01, Volume: 38, Issue:25 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Purines; Pyrazines; Quinazolinones; Rituximab	2020
ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised Trials, 2020, Jul-31, Volume: 21, Issue:1 Topics: Antiviral Agents; Benzamides; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Hospitalization; Humans; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Standard of Care	2020
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. Cancer, 2020, 10-15, Volume: 126, Issue:20 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Humans; Immunotherapy; Male; Middle Aged; Neoplasm Metastasis; Pyrazines; Urologic Neoplasms	2020
Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study. Cancer science, 2021, Volume: 112, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Female; Headache; Humans; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Purpura; Pyrazines; Survival Analysis; Treatment Outcome	2021
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica, 2021, 09-01, Volume: 106, Issue:9 Topics: Adenine; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines	2021
Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood, 2021, 06-17, Volume: 137, Issue:24 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Staging; Pyrazines; Tumor Suppressor Protein p53	2021
BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL. Blood, 2021, 11-11, Volume: 138, Issue:19 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Bispecific; Antigens, CD19; Antineoplastic Agents, Immunological; Benzamides; CD3 Complex; Female; Humans; Immune Checkpoint Inhibitors; Ipilimumab; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazines; T-Lymphocytes	2021
Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study. Haematologica, 2021, 10-01, Volume: 106, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Lymphoma, Large B-Cell, Diffuse; Pyrazines	2021
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies. Leukemia & lymphoma, 2021, Volume: 62, Issue:11 Topics: B-Lymphocytes; Benzamides; Humans; Morpholines; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Pyrimidines	2021
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 11-01, Volume: 39, Issue:31 Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Prognosis; Prospective Studies; Pyrazines; Survival Rate	2021
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. The Lancet. Oncology, 2021, Volume: 22, Issue:10 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Boston; Bridged Bicyclo Compounds, Heterocyclic; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Progression-Free Survival; Pyrazines; Remission Induction; Sulfonamides; Time Factors	2021
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study. The Lancet. Haematology, 2021, Volume: 8, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome	2021
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, Mar-01, Volume: 28, Issue:5 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Head and Neck Neoplasms; Humans; Programmed Cell Death 1 Receptor; Proteomics; Pyrazines; Squamous Cell Carcinoma of Head and Neck	2022
Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma. Leukemia & lymphoma, 2022, Volume: 63, Issue:7 Topics: Adenosine; Benzamides; Humans; Lymphoma, B-Cell; Phosphatidylinositol 3-Kinases; Pyrazines; Quinolines	2022
Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects. British journal of clinical pharmacology, 2022, Volume: 88, Issue:10 Topics: Adult; Benzamides; Biological Availability; Critical Illness; Cross-Over Studies; Healthy Volunteers; Humans; Proton Pump Inhibitors; Pyrazines; Suspensions	2022
Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 10-03, Volume: 28, Issue:19 Topics: Antibodies, Monoclonal, Humanized; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Circulating Tumor DNA; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Pyrazines; Sulfonamides	2022
A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. British journal of haematology, 2022, Volume: 199, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome	2022
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial. The Lancet. Haematology, 2022, Volume: 9, Issue:10 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Cytoreduction Surgical Procedures; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm, Residual; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides	2022
A phase II study of Bruton's tyrosine kinase inhibition for the prevention of anaphylaxis. The Journal of clinical investigation, 2023, 08-15, Volume: 133, Issue:16 Topics: Adult; Agammaglobulinaemia Tyrosine Kinase; Allergens; Anaphylaxis; Arachis; Benzamides; Humans; Peanut Hypersensitivity; Pyrazines	2023

Other Studies

85 other study(ies) available for pyrazines and acp-196

Article	Year
Acalabrutinib for relapsed chronic lymphocytic leukaemia. The Lancet. Oncology, 2016, Volume: 17, Issue:2 Topics: Antineoplastic Agents; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines; Recurrence; Retreatment	2016
Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia, 2017, Volume: 31, Issue:10 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bcl-2-Like Protein 11; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mitochondria; Molecular Targeted Therapy; Neoplasm Proteins; Peptide Fragments; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrazoles; Pyrimidines; Sulfonamides	2017
The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable Haematologica, 2017, Volume: 102, Issue:10 Topics: Antibodies; Antigens, CD20; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines	2017
Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model. Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Oct-01, Volume: 23, Issue:19 Topics: Adenosine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Lymphocytes; Benzamides; Cell Line, Tumor; Cell Proliferation; Class Ia Phosphatidylinositol 3-Kinase; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Neoplasm Proteins; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Quinolines; Tumor Microenvironment	2017
Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors. British journal of haematology, 2018, Volume: 182, Issue:5 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Benzamides; Disease Progression; Drug Resistance; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mutation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Retrospective Studies; Substance Withdrawal Syndrome; Treatment Outcome	2018
Differential Kinobeads Profiling for Target Identification of Irreversible Kinase Inhibitors. ACS chemical biology, 2017, 10-20, Volume: 12, Issue:10 Topics: Acrylamides; Adenine; B-Lymphocytes; Benzamides; Cell Line; Humans; Piperidines; Protein Binding; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyrazines; Pyrazoles; Pyrimidines	2017
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. The Journal of pharmacology and experimental therapeutics, 2017, Volume: 363, Issue:2 Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Benzamides; Dose-Response Relationship, Drug; Humans; Jurkat Cells; Leukocytes, Mononuclear; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines	2017
Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia, 2018, Volume: 32, Issue:4 Topics: Adenine; Adoptive Transfer; Animals; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Cell Movement; Chemokine CCL3; Chemokine CCL4; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Sulfonamides	2018
Acalabrutinib in mantle cell lymphoma. Lancet (London, England), 2018, 02-17, Volume: 391, Issue:10121 Topics: Benzamides; Humans; Lymphoma, Mantle-Cell; Pyrazines	2018
Haematologica, 2018, Volume: 103, Issue:3 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; CD79 Antigens; Clonal Anergy; Endocytosis; Humans; Immunoglobulin M; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction	2018
Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans. Blood, 2018, 06-14, Volume: 131, Issue:24 Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Benzamides; Humans; Imidazoles; Male; Middle Aged; Piperidines; Plaque, Atherosclerotic; Platelet Aggregation; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Thrombosis	2018
Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors. BioMed research international, 2018, Volume: 2018 Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antigens, CD20; B-Lymphocytes; Benzamides; Cell Line, Tumor; Cytotoxins; Humans; Killer Cells, Natural; Leukocytes, Mononuclear; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Rituximab	2018
Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI. Haematologica, 2018, Volume: 103, Issue:12 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Agammaglobulinemia; Benzamides; Blood Platelets; Carrier Proteins; Genetic Diseases, X-Linked; Humans; Mutation; Peptides; Piperidines; Platelet Activation; Platelet Function Tests; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines	2018
Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation. Frontiers in immunology, 2018, Volume: 9 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antigens; B-Lymphocytes; Benzamides; Calcium Signaling; Cell Membrane; Cell Polarity; Cell Proliferation; Cells, Cultured; Immunological Synapses; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Microtubule-Organizing Center; Mutation; Phospholipase C gamma; Piperidines; Protein Transport; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell	2018
A novel Bruton's tyrosine kinase inhibitor, acalabrutinib, suppresses osteoclast differentiation and Porphyromonas gingivalis lipopolysaccharide-induced alveolar bone resorption. Journal of periodontology, 2019, Volume: 90, Issue:5 Topics: Agammaglobulinaemia Tyrosine Kinase; Alveolar Bone Loss; Animals; Benzamides; Bone Marrow Cells; Bone Resorption; Cell Differentiation; Lipopolysaccharides; Mice; NFATC Transcription Factors; Osteoclasts; Porphyromonas gingivalis; Pyrazines; RANK Ligand	2019
Novel Bruton tyrosine kinase inhibitor acalabrutinib quantification by validated LC-MS/MS method: An application to pharmacokinetic study in Sprague Dawley rats. Journal of pharmaceutical and biomedical analysis, 2019, Feb-05, Volume: 164 Topics: Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Drug Stability; Male; Models, Animal; Pyrazines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry; Therapeutic Equivalency	2019
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer, 2019, 02-15, Volume: 125, Issue:4 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cell Transformation, Neoplastic; Cohort Studies; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Longitudinal Studies; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mutation; Piperidines; Prognosis; Pyrazines; Pyrazoles; Pyrimidines	2019
Novel BTK inhibitor acalabrutinib (ACP-196) tightly binds to site I of the human serum albumin as observed by spectroscopic and computational studies. International journal of biological macromolecules, 2019, Apr-15, Volume: 127 Topics: Agammaglobulinaemia Tyrosine Kinase; Benzamides; Binding Sites; Circular Dichroism; Humans; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Pyrazines; Serum Albumin, Human	2019
In brief: Acalabrutinib (Calquence) for mantle cell lymphoma. The Medical letter on drugs and therapeutics, 2018, Nov-05, Volume: 60, Issue:1559 Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents, Immunological; Benzamides; Drug Costs; Humans; Lymphoma, Mantle-Cell; Protein Kinase Inhibitors; Pyrazines; Signal Transduction; Treatment Outcome	2018
Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions. Haematologica, 2019, Volume: 104, Issue:11 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Blood Platelets; Humans; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Thrombosis	2019
Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach. CPT: pharmacometrics & systems pharmacology, 2019, Volume: 8, Issue:7 Topics: Benzamides; Clinical Trials, Phase I as Topic; Computer Simulation; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Models, Biological; Pyrazines	2019
Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2019, Volume: 142 Topics: Benzamides; Biological Availability; Chemistry, Pharmaceutical; Drug Interactions; Fruit and Vegetable Juices; Humans; Models, Biological; Proton Pump Inhibitors; Pyrazines; Solubility	2019
Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part I. Mechanistic modelling of drug product dissolution to derive a P-PSD for PBPK model input. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2019, Volume: 142 Topics: Benzamides; Capsules; Drug Liberation; Micelles; Models, Biological; Particle Size; Pyrazines; Solubility	2019
Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas. British journal of haematology, 2019, Volume: 187, Issue:5 Topics: Adenosine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Humans; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mice, SCID; Protein Kinase Inhibitors; Pyrazines; Quinolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2019
T-cell expression of Bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia. Cellular & molecular immunology, 2020, Volume: 17, Issue:10 Topics: Acute Disease; Agammaglobulinaemia Tyrosine Kinase; Anemia, Aplastic; Animals; Benzamides; Bone Marrow; Cell Proliferation; Graft vs Host Disease; Lymphocyte Activation; Mice, Inbred BALB C; Mice, Inbred C57BL; Phospholipase C gamma; Phosphorylation; Pyrazines; Receptors, Antigen, T-Cell; T-Lymphocytes	2020
Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice. Frontiers in immunology, 2019, Volume: 10 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Benzamides; Cecum; Disease Models, Animal; Heart; Heart Diseases; Inflammasomes; Ligation; Male; Mice; Mice, Inbred C57BL; Piperidines; Protein Kinase Inhibitors; Punctures; Pyrazines; Pyrazoles; Pyrimidines; Sepsis	2019
2019 ASH Annual Meeting. The Lancet. Haematology, 2020, Volume: 7, Issue:1 Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Pyrazines	2020
Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. The Journal of pharmacology and experimental therapeutics, 2020, Volume: 372, Issue:3 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Cell Line; Dose-Response Relationship, Drug; Humans; Inhibitory Concentration 50; Kinetics; Models, Biological; Piperidines; Protein Binding; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines	2020
Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib. Journal of immunotherapy (Hagerstown, Md. : 1997), 2020, Volume: 43, Issue:4 Topics: Adenine; Animals; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers; Combined Modality Therapy; Cytokines; Cytotoxicity, Immunologic; Disease Models, Animal; Humans; Immunotherapy, Adoptive; Lymphocyte Activation; Mice; Neoplasms; Piperidines; Pyrazines; Receptors, Antigen, T-Cell; Receptors, Chimeric Antigen; T-Lymphocytes; Treatment Outcome; Xenograft Model Antitumor Assays	2020
Images in Vascular Medicine. Rumpel-Leede phenomenon in a patient with chronic lymphocytic leukemia treated with acalabrutinib. Vascular medicine (London, England), 2020, Volume: 25, Issue:3 Topics: Agammaglobulinaemia Tyrosine Kinase; Aged, 80 and over; Antineoplastic Agents; Benzamides; Capillary Fragility; Chronic Disease; Ecchymosis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrazines; Risk Factors; Stockings, Compression; Treatment Outcome; Venous Insufficiency	2020
Acalabrutinib for the initial treatment of chronic lymphocytic leukaemia. Lancet (London, England), 2020, 04-18, Volume: 395, Issue:10232 Topics: Antibodies, Monoclonal, Humanized; Benzamides; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines	2020
BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte). Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 07-15, Volume: 26, Issue:14 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Inflammation; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Macrophages; Pandemics; Piperidines; Pneumonia, Viral; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; SARS-CoV-2	2020
Acalabrutinib - a new option in CLL. Nature reviews. Clinical oncology, 2020, Volume: 17, Issue:7 Topics: Antibodies, Monoclonal, Humanized; Benzamides; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines	2020
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19. British journal of haematology, 2020, Volume: 190, Issue:2 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pandemics; Piperidines; Pneumonia, Viral; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; SARS-CoV-2	2020
Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis. The Journal of clinical investigation, 2020, 09-01, Volume: 130, Issue:9 Topics: Agammaglobulinaemia Tyrosine Kinase; Anaphylaxis; Animals; Benzamides; Humans; Immunoglobulin E; Mice; Mice, Inbred NOD; Mice, SCID; Protein Kinase Inhibitors; Pyrazines; Receptors, IgE	2020
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Science immunology, 2020, 06-05, Volume: 5, Issue:48 Topics: Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critical Illness; Female; Follow-Up Studies; Humans; Inflammation; Interleukin-6; Male; Middle Aged; Monocytes; Pandemics; Pneumonia, Viral; Prospective Studies; Pyrazines; Respiration, Artificial; SARS-CoV-2; Treatment Outcome	2020
Occupy BTK: the key to controlling CLL. Blood, 2020, 07-02, Volume: 136, Issue:1 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Pyrazines	2020
Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma. Clinical journal of oncology nursing, 2020, 08-01, Volume: 24, Issue:4 Topics: Adult; Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Humans; Lymphoma, Mantle-Cell; Protein Kinase Inhibitors; Pyrazines	2020
Second cancer incidence in CLL patients receiving BTK inhibitors. Leukemia, 2020, Volume: 34, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Female; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Retrospective Studies; Risk Factors; Young Adult	2020
Aberrantly expressed Bruton's tyrosine kinase preferentially drives metastatic and stem cell-like phenotypes in neuroblastoma cells. Cellular oncology (Dordrecht), 2020, Volume: 43, Issue:6 Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Carcinogenesis; Caspase 3; Cell Line, Tumor; Cell Movement; Cisplatin; Female; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Male; Mice, Inbred NOD; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplastic Stem Cells; Neuroblastoma; Phenotype; Prognosis; Proto-Oncogene Proteins c-akt; Pyrazines; Spheroids, Cellular; STAT3 Transcription Factor	2020
Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest. Cancer, 2020, 10-15, Volume: 126, Issue:20 Topics: Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Benzamides; Humans; Immunotherapy; Pyrazines; Urinary Bladder Neoplasms	2020
Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management. Cancer chemotherapy and pharmacology, 2020, Volume: 86, Issue:4 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Citrus paradisi; Citrus sinensis; Comorbidity; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inducers; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Food-Drug Interactions; Fruit and Vegetable Juices; Hematologic Neoplasms; Humans; Lymphoproliferative Disorders; Piperidines; Polypharmacy; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction	2020
Simultaneous measurement of acalabrutinib, ibrutinib, and their metabolites in beagle dog plasma by UPLC-MS/MS and its application to a pharmacokinetic study. Journal of pharmaceutical and biomedical analysis, 2020, Nov-30, Volume: 191 Topics: Adenine; Animals; Benzamides; Chromatography, High Pressure Liquid; Chromatography, Liquid; Dogs; Percutaneous Coronary Intervention; Piperidines; Pyrazines; Reproducibility of Results; Tandem Mass Spectrometry	2020
Inhibition of Bruton tyrosine kinase by acalabrutinib dampens lipopolysaccharide/galactosamine-induced hepatic damage. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 131 Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; Benzamides; Chemical and Drug Induced Liver Injury; Cytokines; Fusion Regulatory Protein-1; Galactosamine; Lipopolysaccharides; Liver; Male; Mice; Mice, Inbred BALB C; NF-kappa B; Pyrazines	2020
X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure. Frontiers in immunology, 2020, Volume: 11 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Benzamides; Disease Models, Animal; Inflammasomes; Macrophages; Male; Mice; Mice, Inbred CBA; Multiple Organ Failure; Phagocytosis; Piperidines; Protein Kinase Inhibitors; Pyrazines; Sepsis; X-Linked Combined Immunodeficiency Diseases	2020
Restricted mean survival time in patients with chronic lymphocytic leukemia treated with chemotherapy-free regimens as first line. Leukemia & lymphoma, 2021, Volume: 62, Issue:4 Topics: Adenine; Antibodies, Monoclonal, Humanized; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Network Meta-Analysis; Piperidines; Pyrazines; Sulfonamides; Survival Rate	2021
ACP-5862 suppresses esophageal squamous cell carcinoma growth through inducing apoptosis via activation of endoplasmic reticulum stress and ROS production. Biochemical and biophysical research communications, 2021, 01-01, Volume: 534 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle Checkpoints; Cell Line, Tumor; Endoplasmic Reticulum Stress; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Male; Mice, Inbred BALB C; Pyrazines; Reactive Oxygen Species	2021
Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. Leukemia & lymphoma, 2021, Volume: 62, Issue:5 Topics: Agammaglobulinaemia Tyrosine Kinase; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Pyrazines	2021
Genomic profiling is a supplemental diagnostic and therapeutic modality for hairy cell leukemia variant. Annals of hematology, 2021, Volume: 100, Issue:6 Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Genomics; Humans; Leukemia, Hairy Cell; Mutation; Pyrazines	2021
Observations on the use of Bruton's tyrosine kinase inhibitors in SAR-CoV-2 and cancer. Journal of hematology & oncology, 2021, 01-13, Volume: 14, Issue:1 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; COVID-19; COVID-19 Drug Treatment; Cytokines; Drug Repositioning; Gene Expression Regulation; Humans; Piperidines; Pyrazines; SARS-CoV-2	2021
Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. American journal of hematology, 2021, 05-01, Volume: 96, Issue:5 Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Drug Substitution; Exome Sequencing; Follow-Up Studies; Humans; Immunotherapy, Adoptive; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Mutation; Protein Kinase Inhibitors; Pyrazines; Recurrence; Salvage Therapy; Sample Size; Treatment Outcome; Withholding Treatment	2021
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib. Leukemia, 2021, Volume: 35, Issue:5 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Benzamides; Cell Line; Cell Line, Tumor; Chickens; Chlorocebus aethiops; COS Cells; Cysteine; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Threonine	2021
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia, 2021, Volume: 35, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Pyrazines; Retrospective Studies; Survival Rate; United States	2021
Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia. Leukemia & lymphoma, 2021, Volume: 62, Issue:10 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines; Pyrimidines	2021
Comparison of the drug-drug interactions potential of ibrutinib and acalabrutinib via inhibition of UDP-glucuronosyltransferase. Toxicology and applied pharmacology, 2021, 08-01, Volume: 424 Topics: Adenine; Benzamides; Drug Interactions; Glucuronosyltransferase; Humans; Isoenzymes; Molecular Structure; Piperidines; Pyrazines	2021
Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia. Clinical advances in hematology & oncology : H&O, 2021, Volume: 19, Issue:7 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines	2021
Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP-5862, in patients with B-cell malignancies and in healthy subjects using a population pharmacokinetic approach. British journal of clinical pharmacology, 2022, Volume: 88, Issue:2 Topics: Benzamides; Healthy Volunteers; Humans; Models, Biological; Neoplasms; Pyrazines	2022
Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice. European journal of immunology, 2021, Volume: 51, Issue:9 Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; B-Lymphocytes; Benzamides; CD79 Antigens; Extracellular Signal-Regulated MAP Kinases; Immunoglobulin M; Lymphoma, B-Cell; Mice; Mice, Inbred C57BL; Mice, Knockout; NF-kappa B; Phosphatidylinositol 3-Kinases; Phospholipase C gamma; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazines; Receptors, Antigen, B-Cell; Signal Transduction; Syk Kinase	2021
Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study. Cancer medicine, 2021, Volume: 10, Issue:21 Topics: Adenine; Adolescent; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Immunocompromised Host; Infections; Lymphopenia; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazines; Quinazolinones; Retrospective Studies; Risk Factors; Sulfonamides; Young Adult	2021
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica, 2022, 06-01, Volume: 107, Issue:6 Topics: Aged; Atrial Fibrillation; Benzamides; Humans; Hypertension; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Pyrazines	2022
Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis. Journal of the American Heart Association, 2021, 11-16, Volume: 10, Issue:22 Topics: Action Potentials; Adenine; Animals; Arrhythmias, Cardiac; Atrial Fibrillation; Benzamides; Cardiac Electrophysiology; Mice; Myocytes, Cardiac; Piperidines; Pyrazines; Sinoatrial Node	2021
Acalabrutinib monotherapy in patients with Richter transformation. The Lancet. Haematology, 2021, Volume: 8, Issue:12 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Pyrazines	2021
Comment on: "Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients". Haematologica, 2022, 06-01, Volume: 107, Issue:6 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines	2022
Response to Comment on: "Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients". Haematologica, 2022, 06-01, Volume: 107, Issue:6 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines	2022
Is there a role for anti-CD20 antibodies in CLL? Hematology. American Society of Hematology. Education Program, 2021, 12-10, Volume: 2021, Issue:1 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Agents; Antineoplastic Agents, Immunological; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Protein Kinase Inhibitors; Pyrazines; Rituximab; Sulfonamides	2021
Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment. Journal of clinical pharmacology, 2022, Volume: 62, Issue:6 Topics: Adult; Area Under Curve; Benzamides; Humans; Liver Diseases; Pyrazines	2022
Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia. Frontiers in immunology, 2021, Volume: 12 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blood Platelets; Escherichia coli; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Platelet Activation; Platelet Aggregation; Protein Kinase Inhibitors; Pyrazines; Receptors, IgG; Staphylococcus aureus	2021
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia, 2022, Volume: 36, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chlorambucil; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines	2022
Recent data for acalabrutinib in chronic lymphocytic leukemia. Clinical advances in hematology & oncology : H&O, 2022, Volume: 20, Issue:1 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines	2022
A uniquely distributed purpuric drug eruption from acalabrutinib. The Australasian journal of dermatology, 2022, Volume: 63, Issue:2 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Drug Eruptions; Humans; Piperidines; Protein Kinase Inhibitors; Purpura; Pyrazines; Quality of Life	2022
Acalabrutinib CYP3A-mediated drug-drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy. British journal of clinical pharmacology, 2022, Volume: 88, Issue:8 Topics: Area Under Curve; Benzamides; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Fluconazole; Humans; Models, Biological; Pyrazines; Receptor Protein-Tyrosine Kinases	2022
The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact. Haematologica, 2022, 06-01, Volume: 107, Issue:6 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Macrophages; Phagocytosis; Plant Leaves; Protein Kinase Inhibitors; Pyrazines	2022
Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients. Blood, 2022, 07-28, Volume: 140, Issue:4 Topics: Adenine; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Protein Kinase Inhibitors; Pyrazines	2022
Physiologically based pharmacokinetic combined BTK occupancy modeling for optimal dosing regimen prediction of acalabrutinib in patients alone, with different CYP3A4 variants, co-administered with CYP3A4 modulators and with hepatic impairment. European journal of clinical pharmacology, 2022, Volume: 78, Issue:9 Topics: Benzamides; Computer Simulation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Models, Biological; Pyrazines	2022
A validated chiral chromatographic method for the enantiomeric separation of acalabrutinib. Chirality, 2022, Volume: 34, Issue:9 Topics: Amylose; Benzamides; Chromatography, High Pressure Liquid; Pyrazines; Reproducibility of Results; Stereoisomerism	2022
Ventricular arrhythmias and sudden death events following acalabrutinib initiation. Blood, 2022, 11-17, Volume: 140, Issue:20 Topics: Aged; Arrhythmias, Cardiac; Benzamides; Death, Sudden; Heart Failure; Humans; Pyrazines	2022
Exploring the Role of Chemical Reactions in the Selectivity of Tyrosine Kinase Inhibitors. Journal of the American Chemical Society, 2022, 09-14, Volume: 144, Issue:36 Topics: Agammaglobulinaemia Tyrosine Kinase; Benzamides; Protein Kinase Inhibitors; Pyrazines; Tyrosine	2022
Structural characterization of novel hydrolytic and oxidative degradation products of acalabrutinib by LC-Q-TOF-MS, H/D exchange and NMR. Journal of pharmaceutical and biomedical analysis, 2022, Nov-30, Volume: 221 Topics: Acetonitriles; Benzamides; Chromatography, High Pressure Liquid; Deuterium; Drug Stability; Hydrogen; Hydrolysis; Methanol; Oxidation-Reduction; Oxidative Stress; Pyrazines; Tandem Mass Spectrometry	2022
Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib. Haematologica, 2023, 05-01, Volume: 108, Issue:5 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Pyrazines	2023
Tolerability of acalabrutinib in patients with CLL: experience of a tertiary cancer care center. Leukemia & lymphoma, 2023, Volume: 64, Issue:5 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines	2023
Evaluation of bleeding events in patients receiving acalabrutinib therapy. Leukemia, 2023, Volume: 37, Issue:7 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines	2023
Acalabrutinib in chronic lymphocytic leukemia. Expert opinion on pharmacotherapy, 2023, Volume: 24, Issue:5 Topics: Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Pyrazines	2023
Spontaneous hyphema in a patient receiving acalabrutinib. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2023, Volume: 58, Issue:5 Topics: Benzamides; Humans; Hyphema; Iris; Pyrazines	2023
A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia. American journal of hematology, 2023, Volume: 98, Issue:12 Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Pyrazines	2023
Invasive Central Nervous System Aspergillosis in a Patient Receiving Long-term Acalabrutinib Therapy. Mayo Clinic proceedings, 2023, Volume: 98, Issue:11 Topics: Aspergillosis; Benzamides; Central Nervous System; Humans; Pyrazines	2023